Quick ReadPlain-language overview · read this first
HOYA is a long-established Japanese precision optics company. It started with lenses and high-end materials, and its quality is solid. But this report's stance is Watch, not Buy: the company is a good one, but buying it at the current price does not offer an attractive deal.
It makes money mainly from two businesses. One is eye health: eyeglass lenses, contact lenses, myopia-control lenses for teenagers, cataract intraocular lenses, and related products. Demand is steady. As the population ages and myopia becomes more common, this business should gradually move upward. The other business supplies critical materials to semiconductor fabs and hard-drive makers. Its technical barriers are extremely high, making substitution difficult. It earns more money, but it also moves up and down with the industry cycle. In the latest year, the company earned about 253.1 billion yen, and for every 100 yen of products sold, it kept more than 85 yen, showing that it sells highly technical products rather than relying on cheap, high-volume sales.
The issue is price. The company's share price is now about 25,835 yen. Based on the report's calculation, it is already expensive, as if the price has already baked in continued high growth over the next 10 years, leaving almost no room to buy it cheaply. In other words, if the most profitable materials business slows down and the valuation falls, the share price could drop significantly.
The report is most concerned about 3 things: the high-margin materials business is cyclical, so it is unclear whether it can keep earning this much; this year's profit includes one-off gains such as asset sales, which should not be treated as normal; and management does not own much stock, so its interests are not especially tightly aligned with minority shareholders.
So the report's conclusion is: put it on the long-term watchlist and wait patiently. The ideal buy-in price is roughly 16,000 to 20,000 yen. Wait for the price to come down; there is no urgency to chase it now.
The above only explains this report in plain terms and is not investment advice. The stock market involves risk; invest with caution.
LeadHOYA is a Japanese optical precision materials platform with two engines: Life Care, covering eyeglass lenses, contact lenses, endoscopes, and intraocular lenses, contributes 62% of revenue, while Information Technology, covering semiconductor EUV mask blanks and HDD glass substrates, contributes 38% but carries exceptionally high margins of 54%. FY2026 revenue was JPY 947.7 billion, net profit was JPY 253.1 billion, net cash was JPY 531.9 billion, and financial resilience is very strong. Research rating Watch: at the current share price of about JPY 25,835, the stock trades at roughly 38x conservative Owner Earnings, sits in the optimistic valuation range, lacks a sufficient margin of safety, and has an ideal buy range of JPY 16,000 to JPY 20,000.
Conclusion First
Investment rating: Watch
Core view: HOYA is a rare high-quality compound enterprise: one side is a structurally growing eye-health business, and the other is a set of high-barrier industrial materials businesses such as semiconductor mask blanks and nearline HDD glass substrates. Together, they have allowed the company to deliver long-term increases in revenue, net profit, EPS, and cash flow over many years. For the latest fiscal year ended March 2026, revenue was JPY 947.7 billion, net profit attributable to owners of the parent was JPY 253.1 billion, operating cash flow was JPY 278.4 billion, cash on hand was JPY 574.1 billion, and net cash was meaningfully positive, giving the company very strong financial resilience. At the same time, the current share price of about JPY 25,835 corresponds to a Reuters/LSEG forward P/E of about 37.7x, P/E excluding special items of about 34.0x, P/S of about 8.9x, and P/B of about 8.3x. The market has already priced in a great deal of “quality.” The current price looks more like “a good company at a somewhat expensive price” than “a good company at a cheap price.” For investors with a horizon of more than 10 years, I would rather track this business for the long term, but I would not want to initiate a heavy new position at the current valuation.
Does the current price offer a margin of safety: Not obviously. Based on the conservative approach in this report, FY2026 sustainable Owner Earnings are roughly JPY 220.0 billion, implying an Owner Earnings Yield of about 2.6% at the current market capitalization; Reuters shows Japan’s 10-year government bond yield at about 2.741%. Corporate earnings can grow while government bond coupons are fixed, so the two cannot be equated mechanically. Still, for a balanced and somewhat conservative investor, this means the current price does not provide generous risk compensation.
Suitable investor type: HOYA is more suitable for value investors who can understand the business over the long term and accept that a high-quality company may remain “understandable but not necessarily buyable” for long periods. It also suits long-term shareholders who already own it and are willing to keep tracking operating quality rather than stare at share-price fluctuations. It is not very suitable for investors who equate “high quality” directly with “buyable at any price.”
Largest uncertainties: First, the Information Technology business currently has extremely high margins. FY2026 Information Technology pretax margin was still as high as 54.1%, and the durability of this margin is the most important valuation variable. Second, FY2026 profit and free cash flow include certain non-recurring factors, such as cash flow from investment sales, subsidiary disposals, and an elevated “Other” line, so they must be normalized. Third, management’s capital allocation framework has improved clearly, but management’s direct share ownership is not high. Governance quality and capital discipline are strong, yet the degree of “being in the same boat as minority shareholders” is still not especially prominent.
Business Understanding
How HOYA makes money is not hard to understand, while the business is not a single-line story. It is built around two main engines. In the latest fiscal year, Life Care revenue was JPY 590.7 billion, accounting for 62.3% of total revenue. This segment includes health-care-related products such as eyeglass lenses and contact lenses, as well as medical products such as medical endoscopes and intraocular lenses. Information Technology revenue was JPY 354.8 billion, accounting for 37.4%. This mainly includes electronics-related products, such as semiconductor photomask blanks and HDD glass substrates, as well as imaging-related products. In other words, HOYA earns money from “high-precision optical, materials, and manufacturing capabilities,” with value coming from a capability system rather than one single blockbuster product.
From the perspective of customers and charging models, in Life Care, eyeglass lenses and contact lenses serve optical retail and optometry channels, consumers, and medical service systems. The revenue model is essentially unit product price x volume x mix of high-value-added products. The company has also noted that private-brand products and subscription services improve customer retention in its contact lens business. The medical device portion is closer to a combination of equipment and consumables or supporting products. The Information Technology business faces a smaller number of customers with much higher technical requirements. It essentially earns money from the “irreplaceability of key materials” and “yield/process capability.”
Revenue stability is clearly layered. Eyeglass lenses, contact lenses, and myopia-management lenses for children are higher-frequency, more resilient demands driven by population aging and rising myopia rates. The CEO also explicitly describes Life Care as a structural growth business driven by aging and increasing myopia. By contrast, the IT business has better growth and higher margins, but it is tied to semiconductor capital spending, advanced-node progress, and data-center storage cycles, so volatility is higher. This is exactly why HOYA describes itself as a “dual-engine” portfolio: one end is lower-volatility eye health, while the other is higher-growth and more cyclical IT.
On cost structure, HOYA does not rely on low prices and high volumes. It relies on a technical product mix with extremely high gross margins. Reuters/LSEG financial pages show that the company’s gross profit over the past three years was about JPY 657.97 billion, JPY 746.47 billion, and JPY 811.85 billion, respectively, corresponding to gross margins of roughly 85.7% to 86.3%. Such extremely high gross margins alone show that the company is not selling ordinary industrial products that are easy to commoditize. The real burden on profit comes mainly from R&D, manufacturing yield, organizational efficiency, sales promotion, and product mix, rather than raw materials themselves.
In terms of dependency, the exact concentration of the top five customers has not been clearly disclosed in the public materials I reviewed, so this part can only be described conservatively as “unknown.” What can be determined is that the eyeglass lens business is relatively dispersed, while the downstream industries for mask blanks and HDD substrates are naturally more concentrated and have fewer customers. For example, Western Digital lists Seagate and Toshiba directly as HDD competitors in its annual report, which shows that the downstream end-market industry itself is already highly concentrated. HOYA has also disclosed that its current share in nearline HDD glass substrates is about 40%, and its long-term target is to reach 100%. This shows a large opportunity and also shows that the relevant chain is far from a business with “infinitely dispersed customers.”
If “the stock market closes for 5 years; would I be willing to hold it?” is the test, my answer is: I would be willing to own the business, while the current price still gives me pause. The business itself is understandable, cash flow is strong, the balance sheet is stable, and the competitive position is good. The source of hesitation is price.
Business understandability score: 4/5.
Industry and Competitive Landscape
HOYA’s industries cannot be treated as one single category. The eye-health segment is a track with stable long-term demand and structural growth. Both the United Nations and the World Health Organization have stated that the global share of older people will continue to rise. By 2030, 1 in every 6 people globally will be aged 60 or above, and by 2050, the population aged 60 or above will reach 2.1 billion. At the same time, academic research cited in HOYA’s annual report shows that by 2050, the global myopia population may approach half of the world’s population. Eyeglass lenses, contact lenses, myopia-management lenses, and intraocular lenses for cataracts are not temporary themes; they are slow-moving structural variables.
The Information Technology segment is a good track, but with obvious cyclicality. In its 2025 annual report, HOYA positions IT as a high-growth field, with drivers including AI, IoT, and 5G/6G pushing semiconductor miniaturization, as well as growth in global data generation and storage demand. ASML, in reporting related to its 2025 annual report, also emphasized that one of the key drivers of continued semiconductor market growth is AI logic and storage demand. In other words, HOYA benefits from a powerful trend, but not a perfectly smooth trend every year. Capital spending in advanced logic, EUV nodes, and data-center nearline HDDs will fluctuate, so this part is not “utility-like certainty.”
In terms of competitors, HOYA is not fighting one company head-on. It competes in different submarkets. The strongest global competitor in eyeglass lenses is EssilorLuxottica. Important global players in ophthalmic products and intraocular lenses/contact lenses include Alcon. In medical endoscopes, Olympus remains one of the strongest global leaders. In mask blanks and glass materials, HOYA faces Japanese materials companies such as AGC. This is why HOYA looks more like a “high-quality business portfolio platform” than a pure-play single-track company.
HOYA’s most notable industry position is being a big fish in several small and deep ponds, rather than pursuing the absolute largest scale. The company itself explicitly summarizes its market selection principle as “big fish in the small pond,” and describes its core capabilities as the linkage of four elements: materials science, optical design, manufacturing processes, and commercialization. This is more than a polished slogan, because it explains why HOYA can simultaneously make eyeglass lenses, EUV blanks, HDD substrates, and imaging-related high-precision components. These businesses look different on the surface, while their underlying common capabilities are highly consistent.
The industry profit pool is unevenly distributed. In the latest fiscal year, Life Care accounted for 62.3% of revenue, while Information Technology accounted for 37.4% of revenue but contributed much higher margins: FY2026 Information Technology pretax margin was 54.1%, while Life Care pretax margin was 21.9%. This means a large portion of the company’s true excess profit comes from IT materials businesses with higher technical barriers and more concentrated customers, rather than more mass-market medical consumer products. The advantage is a deep profit pool; the risk is higher cyclicality and concentration.
In one sentence: HOYA as a whole is closer to “a good company in good industries, but the most profitable part carries cyclicality.” That makes it more complex than a pure consumer company, and also more durable to hold than a pure semiconductor-cycle stock.
Industry attractiveness score: 4/5.
Moat
HOYA’s first layer of moat is the long-term accumulation of process and materials know-how. The company started with optical glass and, over 85 years, has continuously migrated capabilities in materials formulas, optical design, melting/forming/polishing/coating, and related processes into new businesses, expanding from eyeglass lenses to contact lenses, intraocular lenses, endoscopes, LSI blanks, EUV blanks, and HDD glass substrates. This path dependence itself is a competitive advantage that is hard to build quickly. Competitors may be able to copy a single product in some cases; replicating this capability set of “cross-track reuse of the same underlying capabilities” is much harder.
The second layer of moat is high entry barriers and switching costs in niche markets. Semiconductor mask blanks, EUV-related materials, and high-capacity HDD glass substrates are materials customers use to support critical yields and critical performance. Once they enter a customer’s process flow, the tolerance for switching suppliers is low. Eyeglass lenses may look more “consumerized,” yet high-value-added products such as progressive lenses, photochromic lenses, and children’s myopia-management lenses depend on brand, channel training, professional fitting, product reputation, and repeat purchases. The company also explicitly lists myopia-management lens MiYOSMART iQ and progressive lenses as growth drivers.
The third layer of moat is pricing power and the ability to upgrade product mix. In the eyeglass lens business, the company has repeatedly emphasized growth through high-value-added products. In its Q4 2024 briefing, it also noted that high-value products such as progressive lenses and photochromic lenses drove sales growth. The IT business is even more obvious: FY2025 and FY2026 Information Technology pretax margins both remained around 54%, which is not a profit level ordinary manufacturing businesses can sustain for long. It shows that HOYA charges for “critical process value,” rather than selling glass by the ton.
The fourth layer of moat is capital discipline and business portfolio management capability. The company emphasizes “internal investment first,” reviews each business quarterly, allocates resources toward businesses with high feasibility and high returns, and continues to exit small, weak, non-core businesses. This “portfolio management + exit discipline” is also part of the moat, because many conglomerates are dragged down by low-quality businesses, while HOYA has long actively slimmed down and migrated. The CEO has also explicitly stated that the company will continue to deal with weak businesses and return to the principle of “being a big fish in a small pond.”
The relatively weaker moat lies in limited network effects and data advantages. HOYA is not a platform company. Its moat mainly comes from materials, manufacturing, certification, channels, and product mix, not from the self-reinforcing effect of “more users make the network stronger.” Therefore, if a technology generation changes in a submarket or a customer route shifts, HOYA still needs to keep up through R&D and process capability, rather than relying on network effects.
Is the moat widening, stable, or narrowing? My judgment is: stable overall, widening in certain areas. In eye health, the demand side is widening under the drivers of aging and rising myopia rates. In EUV blanks and high-capacity HDD substrates, medium-term opportunities are also expanding under the pull of AI and data-center-related demand. But this does not mean all businesses are widening at the same pace. Policy disruption in China’s medical device market and impairment in certain businesses also remind us that the moat does not cover all product lines equally.
Can HOYA raise prices in an inflationary environment? The answer is moderately strong. The premium lens business can achieve “price/mix improvement” through product upgrades and mix enhancement. High-barrier IT materials are already closer to critical process components, and their bargaining power is usually better than that of generic materials. Can it remain profitable in an economic downturn? The past few years have partly answered that. In the fiscal year ended March 2021, revenue fell 5.0% year over year, but pretax profit instead grew 8.1% year over year, and pretax margin rose to 29.1%. This shows it is not a fragile enterprise in downturns.
Moat strength score: 4/5.
Management and Capital Allocation
On governance structure, HOYA’s institutional design is a positive. The company is a rare Japanese company with committees. As of June 2025, 5 of the 7 directors on the board were outside directors, giving independent directors a majority. The corporate governance report also states clearly that a majority of independent directors means the board can vote against proposals submitted by management when necessary. For Japanese corporate governance, this is already a relatively strong oversight framework.
Management’s capital allocation thinking saw a clear “rules-based upgrade” in 2025/2026. In its FY2025 Q4 materials, the company laid out its new capital policy very directly: First, “Internal investment, first”: prioritize internal investment, with a focus on expanding EUV blank and HDD substrate capacity. Second, the dividend policy shifts to a progressive dividend policy with a 40% payout ratio. Third, dividends + buybacks will return 100% of free cash flow, and the company plans to reduce the net cash balance to its defined “optimal level” through buybacks over roughly three years. The company estimates that as of FY2025 year-end, net cash excluding direct borrowings was about JPY 570.0 billion, exceeding the optimal level by about JPY 110.0 billion. This framework greatly improves the predictability of capital allocation.
Capital return execution is backed by action. In the FY2025 background explanation, the company acknowledged that cash had previously accumulated and capital efficiency had not been ideal, so it significantly increased capital returns and conducted two buybacks. In the FY2026 annual cash flow statement, payments for share buybacks were JPY 171.97 billion, and dividend payments were JPY 81.90 billion, showing a high level of shareholder returns. In its 2025 report, the company also stated clearly that EPS maintained double-digit growth over the past 10 years, and that EPS growth exceeded net profit growth partly because of continued buybacks and cancellations. Back-calculating from the company’s historical net profit and EPS, weighted average shares outstanding fell from about 380 million shares to 340 million shares between FY2019 and FY2026, a decline of about 10%. This shows buybacks have indeed improved per-share value, rather than serving as a gesture.
My reservations about management mainly fall into two points. First, management’s direct share ownership is low. AGM materials show that CEO Eiichiro Ikeda held only 3,800 shares of the company as of March 31, 2025. Of course, the company also links executives to the medium- and long-term share price through PSUs/RSUs, which partially offsets the lack of direct ownership. Judged by the Buffett-style standard of being “flesh-and-blood tied to shareholders,” the alignment is still modest. Second, the current CEO has served as CEO since 2022, which is a relatively short tenure. He has deep internal experience and IT business experience, while his capital allocation ability across a full cycle still needs time to be tested.
On honesty and candor, HOYA does better than many companies, though not perfectly. The company publicly acknowledged that its previous explanations of capital efficiency were not clear enough, and in its board effectiveness evaluation, it listed “further discussion of important management issues, CEO succession planning, and risk management” as areas for improvement. Such disclosures show the company does not completely avoid problems. At the same time, the “Other” line in FY2026 profit expanded clearly, so investment analysis must normalize it independently and cannot accept the reported figures at face value.
Management and capital allocation score: 3.5/5.
Financial Quality and Owner Earnings
First, here is a table that tries to stay close to the key metrics business owners care about. To avoid confusion across different fiscal-year conventions, this report presents all fiscal years as years ended March, and all amounts except EPS are in billions of yen.
| Fiscal year ended March | Revenue | Net profit attributable to owners | Pretax margin | Operating cash flow | Capex | Operating cash flow - capex | ROE | Estimated weighted average shares |
|---|---|---|---|---|---|---|---|---|
| 2021 | 547.9 | 125.4 | 29.1% | 151.8 | 40.1 | 111.7 | 18.8% | 373.6m |
| 2022 | 661.5 | 164.5 | 31.9% | 190.1 | 34.4 | 155.6 | 22.1% | 368.5m |
| 2023 | 723.6 | 168.6 | 29.8% | 201.8 | 43.5 | 158.4 | 20.8% | 359.0m |
| 2024 | 762.6 | 181.4 | 31.0% | 222.8 | 56.9 | 165.9 | 20.3% | 351.9m |
| 2025 | 866.0 | 202.1 | 30.0% | 235.1 | 60.9 | 174.2 | 20.8% | 347.6m |
| 2026 | 947.7 | 253.1 | 34.6% | 278.4 | 65.7 | 212.7 | 25.4% | 340.2m |
Sources: the company’s year-end quarterly/full-year earnings summaries for fiscal years ended 2021 to 2026; ROE is approximated in this report using average annual equity; shares are estimated as net profit attributable to owners divided by basic EPS.
Over a longer cycle, HOYA’s financial quality is excellent. During FY2019 to FY2026, revenue CAGR was about 7.6%, net profit attributable to owners CAGR was about 11.0%, EPS CAGR was about 12.7%, and operating cash flow CAGR was about 9.6%. EPS grew faster than net profit, reflecting the effect of ongoing buybacks and cancellations. More importantly, this is cash-generative growth, rather than growth that consumes more cash the longer it lasts. Using the simplified metric of “operating cash flow minus capex,” the company has generated substantial cash every year in recent years.
Margins also make the company’s “high quality” very clear. Reuters/LSEG data show FY2024 to FY2026 gross margins of roughly 85.7% to 86.3%. The company’s latest fiscal-year profit from “ordinary operating activities” was JPY 285.2 billion, implying a margin of about 30.1%. By segment, the most profitable is Information Technology: FY2026 pretax margin was 54.1%; Life Care was 21.9%. This shows HOYA does not rely on thin margins and high volume. It earns a large profit pool from a small number of high-value-added businesses.
The match between cash flow and profit is generally good, although FY2026 must be normalized. On one hand, the cash flow statement shows FY2026 operating cash flow of JPY 278.4 billion and capex of JPY 65.7 billion, leaving about JPY 212.7 billion if one only looks at “operating cash flow minus equipment capex.” On the other hand, FY2026 investing cash flow included JPY 41.1 billion from sales of investments, JPY 5.9 billion from sales of subsidiaries, and JPY 3.3 billion from business transfers. This is also why the “Free cash flow” figure in the company summary reached JPY 270.9 billion. In other words, FY2026 reported FCF is elevated and should not be directly treated as annualized cash available to owners.
Now consider working capital. The year-end balance sheets show inventory rising from JPY 77.37 billion in 2021 to JPY 132.48 billion in 2026, and receivables rising from JPY 117.25 billion to JPY 209.61 billion, consistent with scale expansion. In the 2026 cash flow statement, inventory changes released JPY 2.03 billion of cash, receivables consumed JPY 18.62 billion, and the decline in payables consumed another JPY 2.49 billion. In other words, the largest working-capital pressure in the latest year mainly came from receivables, rather than uncontrolled inventory accumulation. It is not a danger signal, although it needs continued monitoring.
The balance sheet is very strong. At FY2026 year-end, cash and cash equivalents were JPY 574.1 billion, interest-bearing debt totaled about JPY 42.2 billion, and net cash was about JPY 531.9 billion. Based on FY2026 profit from “ordinary operating activities” plus depreciation and amortization, net debt/EBITDA is negative. More precisely, net cash/EBITDA is about 1.55x; interest coverage is about 143x. This means that in a downturn, HOYA is almost free from the risk of being crushed by debt.
On accounting quality, I did not see obvious signs of financial fraud in the materials reviewed, although two reminders are necessary. First, FY2026 pretax profit was lifted by the “Other” line and should not be mechanically extrapolated. Second, the key audit matters in the company’s 2025 annual report mention transfer-pricing-related suspense payments under protest. As of March 31, 2025, the related amount totaled about JPY 20.46 billion, and some cases were still under appeal or review. This is not a risk I believe would threaten the company’s survival, although it reminds us that HOYA is not a “perfect company” with no reporting noise.
From an Owner Earnings perspective, I suggest using two layers of estimates. First, the accounting-bridge approach: FY2026 net profit attributable to owners of JPY 253.1 billion + depreciation and amortization of JPY 58.2 billion, minus maintenance capex, which I conservatively set at JPY 55.0 billion to JPY 60.0 billion, and latest-year working-capital consumption of about JPY 19.0 billion, gives roughly JPY 232.0 billion to JPY 237.0 billion. Second, the more conservative cash approach: take operating cash flow of JPY 278.4 billion and subtract equipment capex of JPY 56.6 billion, resulting in about JPY 221.9 billion. Because the latter approach already includes working capital and taxes, and avoids excessive subjectivity around “maintenance capex,” I treat around JPY 220.0 billion as the more prudent conservative Owner Earnings estimate. Based on the current JPY 8,464.7 billion market capitalization, this equals about 38x conservative Owner Earnings. For an excellent company, this is not absurd. But for long-term value investors seeking a margin of safety, it is clearly not cheap.
Valuation and Margin of Safety
First, the principle: PE alone is inadequate for valuing HOYA. It has a large net cash position, ongoing buybacks, and high ROIC. The latest fiscal year also includes investment-disposal gains, elevated IT-cycle profits, and changes in capital return policy. The company’s true cash available for distribution must be examined. In the valuation below, I use “conservative Owner Earnings of about JPY 220.0 billion” as one central anchor, while also considering the company’s own view that excess cash of about JPY 110.0 billion can be gradually released.
Owner Earnings Discount Method
I use a 10-year Owner Earnings discount framework. The point is to observe what kind of long-term growth the current price requires to look reasonable, rather than to calculate a price “precise to the ones digit.”
| Scenario | Starting Owner Earnings | Growth over the next 10 years | Discount rate | Terminal growth | Implied value per share |
|---|---|---|---|---|---|
| Conservative | JPY 210.0 billion to JPY 220.0 billion | 5% to 6% | 9% | 2.0% to 2.5% | JPY 12,000 to JPY 15,000 |
| Base | JPY 220.0 billion to JPY 230.0 billion | 6% to 8% | 8.5% to 9% | 2.5% to 3.0% | JPY 16,000 to JPY 21,000 |
| Optimistic | JPY 235.0 billion to JPY 250.0 billion | 8% to 10% | 8% | 3.0% | JPY 24,000 to JPY 27,000 |
The above is this report’s model estimate, based on the company’s FY2026 operating cash flow, capex, profit structure, net cash policy, and current share price. The current price of JPY 25,835 sits roughly near the optimistic scenario, not the conservative or base scenario. In other words, buying now implicitly bets that the company will maintain very strong compound growth over the next 10 years and that high margins will not materially revert.
Relative Valuation Method
Putting HOYA alongside several strong competitors/comparables from different dimensions makes it clearer how much excellence is already embedded in the price.
| Company | Adjusted/median P/E | P/S | P/B | P/CF | ROI | ROE |
|---|---|---|---|---|---|---|
| HOYA 7741.T | 33.96x | 8.93x | 8.31x | 27.33x | 23.46% | 19.84% |
| Olympus 7733.T | 29.47x | 2.00x | 2.45x | 14.90x | 6.47% | 4.59% |
| AGC 5201.T | 17.93x | 0.75x | 1.02x | 5.61x | 4.93% | 3.33% |
| Alcon | 40.56x | 3.16x | 1.48x | 15.54x | 2.86% | 2.62% |
Source: Reuters/LSEG pages available on the day or most recently.
The table gives a clear conclusion: HOYA is materially more expensive and materially more profitable. The real question is whether it remains attractive at this level. My answer is: it deserves long-term respect, with no need to chase it at any price. Its valuation premium over more traditional Japanese companies such as Olympus and AGC can largely be explained by higher ROE/ROI, net cash, and better business quality. Compared with global ophthalmology companies such as Alcon, HOYA is still not cheap on P/S, P/B, or P/CF. Put more directly: HOYA is a premium asset, and the current premium is already thick.
Asset and Liquidation Value Method
HOYA has little appeal as a stock bought with net assets as a “floor.” At FY2026 year-end, equity attributable to owners of the parent per share was about JPY 3,041.71. Cash and cash equivalents were JPY 574.1 billion, interest-bearing debt was about JPY 42.2 billion, and net cash was about JPY 531.9 billion, equivalent to about JPY 1,600 per share. Even after considering some long-term financial assets, this remains very far from the current JPY 25,835 share price. Management itself also defines about JPY 110.0 billion of cash as above the optimal net cash level, which indicates that most cash is regarded as operating flexibility and M&A reserve, rather than completely redundant. In other words, this is a cash-flow compounder, not an asset stock. Almost the entire investment case rests on the continued compounding of future high-quality cash flow.
Combining the three methods, my valuation conclusion is: Conservative intrinsic value range: JPY 12,000 to JPY 18,000 per share Reasonable intrinsic value range: JPY 18,000 to JPY 24,000 per share Optimistic intrinsic value range: JPY 24,000 to JPY 28,000 per share
At the current JPY 25,835, HOYA is roughly in the upper half of the optimistic intrinsic value range, with an approximately 8% to 43% premium to the “reasonable intrinsic value range” and no margin of safety relative to the “conservative intrinsic value range.”
Therefore, my price framework is: Ideal buy price range: JPY 16,000 to JPY 20,000 Acceptable holding price range: JPY 20,000 to JPY 26,000 Clearly overvalued price range: above JPY 28,000
This does not mean the stock will definitely fall above JPY 28,000. It means that at that price, long-term returns depend more on “perfect execution + no valuation derating,” a setup conservative capital allocation should avoid underwriting.
Margin of safety conclusion: insufficient.
Risks, Comparisons, and Final Conclusion
The most important risk is permanent capital loss, rather than short-term volatility. For HOYA, the key risks mainly fall into the following categories. One category is competition and technological substitution risk: if advanced semiconductor manufacturing routes change, competition in EUV-related materials intensifies, or nearline HDDs are eroded by other storage media faster than expected over the long term, the IT business’s high margins could decline. The company currently views IT as a high-growth area, but this part inherently depends more on technology iteration and capital spending cycles. Another category is policy and regional risk: the company has clearly disclosed that China’s anti-corruption policies, volume-based procurement, and economic slowdown have pressured medical endoscopes and intraocular lenses. If China’s policy environment remains tight, part of Life Care’s margins will be affected. Another category is overvaluation risk: current market pricing already embeds high quality and long-term growth. Once margins normalize or growth slows, even if HOYA remains a good company, valuation multiple compression may prevent investors from earning satisfactory returns for a long time. There is also accounting normalization and tax dispute risk: FY2026 profit contains a clear impact from Other/asset disposals, and the 2025 annual report also lists transfer-pricing-related suspense payments under protest. These factors may not constitute serious operating problems, although they can make reported profit deviate from sustainable earnings.
The strongest bear case is actually very powerful: the mistake with HOYA may be paying too much for an excellent company. Investors who are bearish on HOYA may well acknowledge that it is an excellent company. What they see is: First, the current valuation already implies continued high growth over the next 10 years; Second, the most profitable IT business is clearly cyclical; Third, FY2026 free cash flow and profit both need normalization, so the best year cannot be treated as the norm; Fourth, for a company with ample net cash, excellent governance, and high quality, the market often assigns a high price for a long time, but that also means greater room for disappointment.
What facts would make me admit the judgment was wrong? If any of the following occur, I would revisit the bullish thesis: If the Information Technology business margin stays below 45% and shows no sign of recovery within 2 to 3 years; if organic growth in eyeglass lenses and myopia-management products slows materially, indicating that structural demand has not translated into company share/price growth; if management starts pursuing large, high-premium, low-return acquisitions, deviating from the principle of “internal investment first and strict valuation”; or if the cash return policy deteriorates into a focus on scale expansion without emphasizing per-share value.
Compared with other opportunities, my judgment is: Compared with its strongest competitors, HOYA’s operating quality and capital returns are likely better than more traditional Japanese companies such as Olympus and AGC, but its valuation is also far above theirs. Compared with Alcon, HOYA shines more in capital efficiency, but the market has already assigned it a full premium. Compared with broad-based indexes, if I had to choose today between “HOYA at the current price” and “a low-cost broad-based index,” I would lean toward the latter. The reason is diversification, lighter current valuation pressure, and no reliance on one company maintaining extremely high margins. Compared with the risk-free rate, using this report’s most conservative Owner Earnings approach, HOYA’s current yield has almost no adequate safety cushion over Japan’s 10-year government bond yield. So if your portfolio can hold only 5 assets, HOYA’s business deserves a place on the candidate list, but at the current price, I would not put it in the top five for a new position.
Below is the Checklist organized as requested.
| Checklist item | Conclusion |
|---|---|
| Can I understand this business? | Pass |
| Does it have long-term stable demand? | Pass |
| Does it have a durable moat? | Pass |
| Does it have pricing power? | Pass |
| Can it generate stable free cash flow? | Pass |
| Are its capital returns excellent? | Pass |
| Is management trustworthy? | Pass |
| Is capital allocation rational? | Pass |
| Is the balance sheet sound? | Pass |
| Is valuation below intrinsic value? | Fail |
| Is the margin of safety sufficient? | Fail |
| Would I feel comfortable holding it for the long term? | Pass |
| What key facts would make me sell? | Identified |
| Am I only interested because the share price rose or because of market sentiment? | Needs self-check |
The above conclusions are based on the preceding analysis: operations, moat, cash flow, and governance pass on multiple dimensions; the main bottleneck is price.
Final Investment Conclusion
【Final Rating】 Watch
【One-Sentence Investment Thesis】 HOYA is very likely a high-quality company worth owning for the long term, but buying at the current price makes returns depend more on “continued perfection” than on a “margin of safety.”
【Core Bull Case】
Eye-health demand is driven by aging and rising myopia rates, giving long-term demand structural support.
The IT business has high barriers and high margins in key materials such as EUV blanks and HDD substrates, with FY2026 Information Technology pretax margin still reaching 54.1%.
Revenue, net profit, EPS, and operating cash flow continued to grow from 2019 to 2026, and EPS grew faster than net profit, reflecting high-quality buybacks.
The balance sheet is extremely strong, with net cash of about JPY 531.9 billion at FY2026 year-end and very high interest coverage.
The new capital policy is clearer: internal investment first, 40% progressive dividend payout, dividends plus buybacks returning 100% of free cash flow, and a plan to recover excess cash.
【Core Bear Case】
Current valuation is already expensive. The current price is roughly near the optimistic scenario valuation, and the margin of safety is insufficient.
The most profitable IT business has obvious cyclicality, and margin normalization would significantly compress valuation support.
FY2026 profit and FCF include lifts from asset disposals and the Other line, so reported figures cannot be treated directly as normal.
The governance structure is excellent, but management’s direct share ownership is not high, so shareholder alignment is not maximal.
China policy, semiconductor cycles, and data-storage cycles may cause periodic pullbacks in parts of the business.
【Key Assumptions】
Eyeglass lenses, myopia management, and contact lenses can sustain mid-single-digit to high-single-digit growth.
The high-barrier position of mask blanks and HDD substrates is not materially weakened.
Overall ROE can remain near about 20% over the long term, rather than falling back to the low-to-mid teens.
Management continues to execute with the current capital discipline and does not pursue large acquisitions that damage returns.
【Fair Buy Price】 JPY 16,000 to JPY 20,000 per share. The basis is that a clear discount to the “reasonable intrinsic value range” is needed to meet the margin-of-safety requirement for a balanced and somewhat conservative investor.
【Target Holding Period】 Suitable only with a more than 10-year holding premise. If you cannot hold for 10 years, this stock can easily trigger emotional decisions in the medium to short term because of its high valuation.
【Expected Annualized Return】
Conservative scenario: 3% to 5%
Base scenario: 6% to 8%
Optimistic scenario: 9% to 11%
This is a subjective estimate based on this report’s Owner Earnings model, current price, buyback/dividend policy, and possible valuation mean reversion. It is not a promised market return.
【Maximum Loss Risk】 If the IT business margin steps down materially, growth slows, and the market compresses valuation from 34x to 38x sustainable Owner Earnings to 20x to 25x, then a share price returning to JPY 12,000 to JPY 15,000 is not unimaginable. That would imply roughly 40% to 55% downside from the current price. The worst case comes from an “excellent company” losing its valuation aura, rather than bankruptcy.
【Tracking Indicators】
Information Technology revenue growth and pretax margin
Whether Life Care margin can steadily return to and exceed 20%
Penetration of high-value-added products such as MiYOSMART iQ and progressive lenses
Capacity expansion execution and customer adoption for EUV blanks and HDD substrates
Operating cash flow and “operating cash flow minus equipment capex”
Buyback amount, number of shares cancelled, and total share count changes
Cash/debt and the company-defined “optimal net cash level”
China-market policy disruptions to cataract IOLs and medical endoscopes
Share of profit contributed by one-off Other/asset disposal gains
Progress on tax disputes and suspense payments
【Signals That Trigger Reassessment】
IT business margin is materially below 45% for multiple consecutive years
Eye-health business growth stays below structural industry demand for a long period
High-return businesses suffer sustained impairment, gross-margin decline, or customer losses
Management conducts large high-premium acquisitions
Shareholder return policy is weakened or cash begins to pile up sharply again
Tax/accounting uncertainty expands materially
【Open Questions and Limitations】
The company has not clearly disclosed the revenue share of its top five customers in public materials, so precise quantification of “customer concentration” remains insufficient.
For a fully rigorous 5- to 10-year gross margin and ROIC series, it would be better to extract data systematically from all annual reports and notes year by year.
HOYA spans multiple high-barrier niche markets, and strict comparables are inherently imperfect, so relative valuation can only serve as a supporting tool, not the primary anchor.
【Final Recommendation】 Place HOYA on a “high-priority watchlist” instead of a “must buy today” list. It is very likely an excellent company that can continue creating value, while excellence is no substitute for a margin of safety. For long-term value investors, the most important task is waiting until the price you pay is conservative enough, rather than merely proving that the company is good. At this stage, I would choose long-term respect and patient waiting.
This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.
Full report
Sign in to read the full report
Sign up free to unlock the full text, the Baillie growth scorecard, and full-text search.
Log in / Sign up free